everolimus / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

162 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
everolimus / Generic mfg.
NCT01115803: A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Terminated
1b
29
US, Europe
LY2584702, Erlotinib, Everolimus
Eli Lilly and Company
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
06/11
06/11
NCT01677390: A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Terminated
1b
4
US
SGN-75, everolimus
Seagen Inc.
Renal Cell Carcinoma
12/13
12/13
NCT01508104: Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

Terminated
1b
19
US
BEZ235, Everolimus, RAD001
University of Cincinnati, Novartis
Cancer
02/14
12/14
NCT02106507: ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Checkmark PSA response in metastatic castration-resistant prostate cancer
May 2015 - May 2015: PSA response in metastatic castration-resistant prostate cancer
Completed
1b
9
US
apalutamide, Everolimus
Memorial Sloan Kettering Cancer Center, Aragon Pharmaceuticals, Inc.
Prostate Cancer
06/21
06/21
ACTRN12612000136808: Phase I study of RAD001 (Everolimus) in combination with Fluvastatin and Zoledronic acid in patients with solid tumours

Active, not recruiting
1
25
 
St George Hospital, Novartis Pharmaceuticals Australia Pty Ltd
Advanced cancers
 
 
NCT00352443: S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Checkmark Combination of lapatinib & everolimus in advanced cancer
Sep 2013 - Sep 2013: Combination of lapatinib & everolimus in advanced cancer
Completed
1
66
US
everolimus, lapatinib ditosylate
Southwest Oncology Group, National Cancer Institute (NCI)
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
08/07
09/13
NCT00613132: Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Completed
1
78
US
Gleevec, RAD001, and Hydroxyurea, Gleevec-Imatinib-Imatinib mesylate, RAD001-Everolimus, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide
Annick Desjardins, Novartis Pharmaceuticals
Glioblastoma, Gliosarcoma
08/08
01/13
NCT00187174: Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Completed
1
41
US
Everolimus
St. Jude Children's Research Hospital, Novartis
Tumors, Brain Tumors, Rhabdomyosarcoma, Sarcoma, Soft Tissue
10/08
10/08
NCT00680758: Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Completed
1
18
US
cisplatin, Platinol, everolimus, RAD001, paclitaxel, Taxol
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Breast Cancer
08/09
12/10
NCT00478634: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Completed
1
19
US
RAD001, Cetuximab, Irinotecan
Novartis Pharmaceuticals
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
09/09
09/09
NCT00655655: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Completed
1
96
US
everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, vatalanib, CGP-79787, PTK787/ZK 222584, pharmacological study, pharmacological studies, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, DCE-MRI, ultrasound imaging, ultrasonography, ultrasound, ultrasound test
Mayo Clinic, National Cancer Institute (NCI)
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
09/09
01/18
NCT00373815: Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease

Terminated
1
10
Europe
Everolimus
University Hospital Tuebingen
Graft Versus Host Disease
 
10/09
NCT00457119: Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients

Checkmark + carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced NSCLC
Apr 2013 - Apr 2013: + carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced NSCLC
Completed
1
69
US, Europe, RoW
RAD001, Everolimus
Novartis Pharmaceuticals
Non Small Cell Lung Cancer
11/09
11/09
NCT00729638: RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

Completed
1
28
US
RAD001, lenalidomide
Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin
Multiple Myeloma
11/09
11/09
NCT00422344: A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma

Completed
1
20
US
RAD001, Sunitinib
Memorial Sloan Kettering Cancer Center, Novartis
Renal Cell Carcinoma, Kidney Cancer
02/10
02/10
NCT00544999: Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Unknown status
1
21
Europe
cytarabine, daunorubicin hydrochloride, everolimus, laboratory biomarker analysis, pharmacological study
Institut de Recherche Clinique sur les Cancers et le Sang
Leukemia
04/10
 
NCT00703807: Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers

Checkmark In combination with oral topotecan for recurrent & adv endometrial cancer
Feb 2014 - Feb 2014: In combination with oral topotecan for recurrent & adv endometrial cancer
Completed
1
10
US
Topotecan, Hycamtin, RAD001, Everolimus
Yale University, Novartis
Endometrial Cancer
05/10
05/10
NCT00426530 / 2006-001595-20: Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Completed
1
50
Europe
everolimus (RAD001)
Novartis Pharmaceuticals
Breast Neoplasms, Neoplasm Metastasis
06/10
06/10
NCT00303732: Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors

Completed
1
37
US
RAD001 (everolimus), Afinitor, PTK787 (vatalanib)
Daniel George, MD, Novartis
Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific
08/10
08/12
NCT00807755: Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

Terminated
1
5
US
Carboplatin, Paraplatin, Etoposide, Eposin, Etopophos, Vepesid, VP-16, RAD001, Everolimus, Afinitor
University of California, Davis, Novartis
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
08/10
12/11
NCT00387400: Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Completed
1
32
Canada
everolimus, temozolomide, microarray analysis, immunohistochemistry staining method
NCIC Clinical Trials Group
Brain and Central Nervous System Tumors
09/10
01/12
NCT00466466: Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients

Checkmark In combination with cisplatin & etoposide as 1st line therapy in pts with extensive-stage SCLC
Dec 2013 - Dec 2013: In combination with cisplatin & etoposide as 1st line therapy in pts with extensive-stage SCLC
Completed
1
20
Europe, US
Everolimus, RAD001
Novartis Pharmaceuticals
Small-Cell Lung Cancer
11/10
 
NCT00968591: Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency

Completed
1
34
Europe, RoW
Everolimus
Novartis Pharmaceuticals
Hepatic Insufficiency
11/10
 
NCT00434174: Safety of Everolimus and Pemetrexed in Lung Cancer Patients

Completed
1
48
Europe, RoW
Everolimus, RAD001, Affinitor, Pemetrexed
Novartis Pharmaceuticals
Non Small Cell Lung Cancer
12/10
12/10
NCT00967928: Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer

Withdrawn
1
0
US
RAD001, Afinitor, Everolimus, Cisplatin, CDDP, Platinol, External Beam Whole Pelvis Radiation Therapy
Accelerated Community Oncology Research Network, Novartis Pharmaceuticals
Cervical Cancer
12/10
12/10
NCT00927966: RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms

Completed
1
21
US
RAD001, CP-751,871
Suzanne George, MD, Brigham and Women's Hospital, Novartis, Pfizer
Sarcoma, Solid Tumor
01/11
01/11
NCT00496600: Phase I Study of Patupilone and RAD001

Completed
1
42
US
Patupilone, RAD001
University of Medicine and Dentistry of New Jersey, Novartis Pharmaceuticals, National Cancer Institute (NCI)
Refractory Malignancy
02/11
02/11
NCT00456833 / 2004-003017-16: Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Checkmark In previously treated pts with adv NSCLC
Dec 2013 - Dec 2013: In previously treated pts with adv NSCLC
Completed
1
248
Europe, Canada, US, RoW
RAD001, erlotinib
Novartis Pharmaceuticals
Non Small Cell Lung Cancer
03/11
 
NCT01148628: Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors

Unknown status
1
54
Europe
RAD 001 in combination with Caelyx
Southern Europe New Drug Organization, Novartis, Schering-Plough
Advanced Solid Tumors
03/11
12/11
NCT01057277: RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer

Terminated
1
3
US
RAD001(Afinitor), Afinitor
howard safran, Rhode Island Hospital, The Miriam Hospital, Memorial Hospital of Rhode Island, Roger Williams Medical Center
Head and Neck Cancer
05/11
06/11
NCT01332279: Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Withdrawn
1
0
US
everolimus, RAD001, Afinitor, 42-O-(2-hydroxy)ethyl rapamycin, erlotinib hydrochloride, erlotinib, TARCEVA, OSI-774, biopsy, biopsies, laboratory biomarker analysis, immunohistochemistry staining method, immunohistochemistry, polyacrylamide gel electrophoresis, electrophoresis, polyacrylamide gel, pharmacological study, pharmacological studies, external beam radiation therapy, EBRT, microarray analysis, gene expression profiling
Fox Chase Cancer Center
Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
05/11
05/11
NCT00828594 / 2008-004096-21: Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

Checkmark P1 data
Sep 2011 - Sep 2011: P1 data
Checkmark P1 data
Jun 2011 - Jun 2011: P1 data
Terminated
1
130
US, Europe, RoW
RAD001, RAD001, sorafenib
Novartis Pharmaceuticals
Hepatocellular Carcinoma
06/11
06/11
NCT01063478: Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC

Terminated
1
3
US
RAD001 (in addition to standard radiation and chemotherapy), RAD001 (Everolimus)
University of Chicago, Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
06/11
01/12
NCT01637194: Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer

Completed
1
12
US
everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, cetuximab, C225, C225 monoclonal antibody, IMC-C225, MOAB C225, monoclonal antibody C225, pharmacological study, pharmacological studies, laboratory biomarker analysis
Fox Chase Cancer Center, National Cancer Institute (NCI)
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Colon Cancer, Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Colon Cancer, Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Tongue Cancer
07/11
07/11
NCT01049620: RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
1
40
RoW
RAD001, Capecitabine, Oxaliplatin
Asan Medical Center
Advanced Gastric Cancer
07/11
09/13
BEL, NCT01055795: Safety Study of Bevacizumab, Everolimus and LBH589 () for Advanced Solid Tumors

Checkmark P1 data (Solid)
Jun 2012 - Jun 2012: P1 data (Solid)
Completed
1
14
US
Bevacizumab, Everolimus and LBH589
Herbert Hurwitz, Novartis, Genentech, Inc.
Advanced Solid Tumors
08/11
05/12
NCT00423865: Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Completed
1
30
US
cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
09/11
09/11
NCT00955773: A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Checkmark In combination with everolimus in pts with adv solid tumors
Oct 2014 - Oct 2014: In combination with everolimus in pts with adv solid tumors
Checkmark P1 data
Nov 2011 - Nov 2011: P1 data
Checkmark P1b data-AACR-NCI-EORTC
More
Completed
1
64
US, Europe
GSK1120212 plus everolimus
GlaxoSmithKline
Cancer
11/11
11/11
NCT00473005: Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast

Terminated
1
18
US
Capecitabine, Xeloda, Roche, RAD001, Everolimus, Zortress, Certican, Afinitor
Stanford University, Novartis
Breast Cancer
12/11
12/11
NCT01058408: RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer

Terminated
1
3
US
Intensity modulated radiotherapy, IMRT, RAD001, cisplatin
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Novartis
Head and Neck Cancer
02/12
 
NCT00253318: RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Terminated
1
15
US
Docetaxel, Taxotere, RAD001, Dexamethasone, Decadron
M.D. Anderson Cancer Center, Novartis Pharmaceuticals
Breast Cancer
04/12
04/12
ACTRN12610000405011: This study is examining the safety and tolerability of a new drug (Everolimus) in combination with chemotherapy in the treatment of relapsed adult acute lymphobastic leukaemia

Terminated
1
20
 
Australasian Leukaemia and Lymphoma Group, Novartis Pharmaceuticals Australia Pty Ltd
acute lymphobastic leukaemia (ALL)
 
 
NCT01079481: Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer

Checkmark Everolimus+paclitaxel in pts with SCLC
Aug 2013 - Aug 2013: Everolimus+paclitaxel in pts with SCLC
Completed
1
21
RoW
taxol plus everolimus
Samsung Medical Center
Small Cell Lung Cancer
05/12
04/13
S387, NCT01042782: Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction

Checkmark Everolimus & mitomycin C for pts with mets esophagogastric adenocarcinoma
Aug 2013 - Aug 2013: Everolimus & mitomycin C for pts with mets esophagogastric adenocarcinoma
Completed
1
16
Europe
RAD001 and MitomycinC, RAD001 (everolimus)
Krankenhaus Nordwest
Advanced Gastric Cancer, Advanced Cancer of the Esophagogastric Junction
08/12
08/12
NCT01096199: A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)

Terminated
1
35
RoW
TS-ONE, Cisplatin, RAD001
National University Hospital, Singapore
Cancer
09/12
 
NCT00276575: Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

Completed
1
65
US
bevacizumab, erlotinib hydrochloride, everolimus
Herbert Hurwitz, MD, National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
10/12
09/14
NCT01714765: Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer

Checkmark Combination of everolimus & dovitinib in VEGF refractory clear RCC
Jun 2014 - Jun 2014: Combination of everolimus & dovitinib in VEGF refractory clear RCC
Checkmark ASCO-GU 2014
Jan 2014 - Jan 2014: ASCO-GU 2014
Checkmark
More
Completed
1
17
Europe
Dovitinib, Everolimus
Queen Mary University of London, Novartis
Metastatic Clear Cell Renal Cancer
10/12
10/12
NCT01074086: Phase I Study in RAD 001 Patients With Relapse AML

Checkmark In combination with chemo for AML pts in first relapse
Sep 2013 - Sep 2013: In combination with chemo for AML pts in first relapse
Checkmark GOELAMS study: AML
Jan 2013 - Jan 2013: GOELAMS study: AML
Completed
1
31
Europe
RAD 001, everolimus
French Innovative Leukemia Organisation, Novartis Pharmaceuticals
AML
12/12
12/12
Rad/Sutent, NCT00788060: A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

Completed
1
5
US
Everolimus (RAD001), RAD001, Sunitinib (Sutent), Sutent
Daniel George, MD, Novartis, Pfizer
Renal Cell Carcinoma
12/12
12/12
NCT00943956: Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer

Checkmark ASCO-GU 2013
Feb 2013 - Feb 2013: ASCO-GU 2013
Completed
1
30
Europe
bicalutamide, everolimus, leuprolide acetate, external beam radiation therapy
Institut du Cancer de Montpellier - Val d'Aurelle
Prostate Cancer
12/12
12/12
COBRA, NCT00849550: Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.

Checkmark Capecitabine, oxaliplatin, bevacizumab & everolimus in adv solid tumors
Apr 2014 - Apr 2014: Capecitabine, oxaliplatin, bevacizumab & everolimus in adv solid tumors
Completed
1
32
US
capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)
Herbert Hurwitz, Roche-Genentech, Novartis
Unspecified Adult Solid Tumor, Protocol Specific, Cancer
12/12
12/12
NCT00962507: Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Completed
1
11
US
everolimus, panobinostat, laboratory biomarker analysis, pharmacological study
City of Hope Medical Center, National Cancer Institute (NCI)
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
01/13
01/13
NCT00942682: Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Checkmark sorafenib + everolimus
Mar 2013 - Mar 2013: sorafenib + everolimus
Completed
1
21
US
Sorafenib, RAD001
Dana-Farber Cancer Institute, Novartis, Bayer
Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
03/13
03/13
NCT00610948: Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment

Completed
1
74
US
panitumumab, Vectibix, everolimus, Afinitor, fluorouracil, 5FU, leucovorin calcium, oxaliplatin, Eloxatin
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
05/13
01/16
NCT01154335: Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

Checkmark In combination with everolimus in pts with refractory mCRC
Oct 2014 - Oct 2014: In combination with everolimus in pts with refractory mCRC
Completed
1
18
US
OSI-906, Everolimus
SCRI Development Innovations, LLC, Novartis Pharmaceuticals, OSI Pharmaceuticals
Metastatic Colorectal Cancer
05/13
05/13
AML1208, NCT01154439: Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
1
11
Europe
cytarabine, Mini-ICE regimen (idarubicin, cytarabine and etoposide)., etoposide, everolimus, RAD001, idarubicin, mitoxantrone hydrochloride
Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia
05/13
09/15
EVAX, NCT01334073: Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors

Completed
1
19
Europe
Axitinib plus everolimus
University Hospital, Bordeaux
Malignant Advanced Solid Tumors, Carcinoma, Renal Cell
05/13
01/15
EVESOR, NCT01932177: a Phase 1 Trial of Everolimus and Sorafenib

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Unknown status
1
60
Europe
Everolimus and sorafenib
Hospices Civils de Lyon
Metastatic or Locally Advanced Solid Tumors
05/13
10/15
NCT00985374 / 2008-005806-38: A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Terminated
1
11
US, Europe
RAD001, RG1507
Hoffmann-La Roche
Neoplasms
06/13
06/13
NCT00858663: Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer

Completed
1
13
US
intensity modulated radiation therapy, RAD001 (everolimus) + Cisplatin
Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals
Head and Neck Cancer
07/13
07/13
NCT00636922: Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia

Unknown status
1
40
RoW
RAD001(Everolimus), Everolimus
Bayside Health
Acute Myeloid Leukemia
07/13
01/14
NCT00935961: RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

Checkmark + doce + cisplatin
Feb 2013 - Feb 2013: + doce + cisplatin
Completed
1
18
US
RAD001 + docetaxel + cisplatin
Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals
HEAD & NECK Cancer
08/13
08/13
NCT00384969: Sorafenib and RAD001 Renal Cell Carcinoma

Completed
1
21
US
RAD001 and Sorafenib
University of California, San Francisco, Novartis
Renal Cell Carcinoma
12/13
03/14
NCT00401778: Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Completed
1
33
US
RAD001, Everolimus
Emory University
Lung Cancer
12/13
12/13
NCT01152801: Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

Checkmark
Mar 2013 - Mar 2013: 
Completed
1
64
RoW
Everolimus (RAD001)
Novartis Pharmaceuticals
Metastatic Renal Cell Carcinoma
12/13
12/13
NCT00622258: A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed
1
13
Japan
Everolmus, RAD001
Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma
01/14
01/14
SORAVE, NCT00933777: - Sorafenib and Everolimus in Solid Tumors

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark WCLC 2013
Oct 2013 - Oct 2013: WCLC 2013
Checkmark ASCO 2013
More
Completed
1
36
Europe
Combination of sorafenib and everolimus, Nexavar, RAD001
University of Cologne
Unspecified Adult Solid Tumor, Protocol Specific, Non-Small Cell Lung Cancer
02/14
02/15
NCT00426556 / 2006-001596-37: Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Checkmark In combination with trastuzumab & paclitaxel in pts with HER2+ve adv BC
Oct 2013 - Oct 2013: In combination with trastuzumab & paclitaxel in pts with HER2+ve adv BC
Completed
1
88
US, Europe
Everolimus, RAD001, Trastuzumab, Paclitaxel
Novartis Pharmaceuticals
Metastatic Breast Cancer
03/14
03/14
COOPERATE-1, NCT01263353: Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Completed
1
36
Europe
Pasireotide LAR followed by Pasireotide LAR + Everolimus, Everolimus followed by Pasireotide LAR + Everolimus
Novartis Pharmaceuticals
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
03/14
03/14
PHOENIX I, NCT01217177: A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer

Completed
1
14
RoW
everolimus, RAD001
Novartis Pharmaceuticals
Locally Advanced Cervical Cancer
04/14
04/14
NCT01324492: Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Completed
1
16
RoW
RAD001, Everolimus
Novartis Pharmaceuticals
Lung Neuroendocrine Neoplasm
06/14
06/14
RAD001, NCT01167530: Study to Evaluate in Combination With Radiotherapy in Non-small Cell Lung Cancer

Checkmark TAT 2013
Mar 2013 - Mar 2013: TAT 2013
Unknown status
1
36
Europe
Everolimus
Gustave Roussy, Cancer Campus, Grand Paris, Novartis
Non-small Cell Lung Cancer, Locally Advanced Disease
07/14
07/14
NCT00949949: Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

Completed
1
38
US
everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, cisplatin, CACP, CDDP, CPDD, DDP
Mayo Clinic, National Cancer Institute (NCI)
Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific
07/14
07/14
NCT01204476: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Checkmark ASCO-GI 2014
Jan 2014 - Jan 2014: ASCO-GI 2014
Checkmark P1 data - ASCO
Jun 2012 - Jun 2012: P1 data - ASCO
Completed
1
27
US
Cixutumumab, Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12, IMC-A12, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Laboratory Biomarker Analysis, Octreotide Acetate, D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt), Longastatin, Longastatina, Samilstin, Sandostatin, Sandostatin Lar Depot, Sandostatina, Sandostatine, SMS 201-995, SMS 201-995 AC, Pharmacological Study
National Cancer Institute (NCI)
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
07/14
 
NCT01642732: Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

Terminated
1
1
US
Everolimus, lupron, bicalutamide, and radiation, afinitor, RAD-001, Casodex, Leuprolide, Eligard
University of Michigan Rogel Cancer Center, Novartis Pharmaceuticals
Prostate Cancer
08/14
08/14
BEP, NCT00586443: Study Phase I (Bevacizumab, Everolimus, Panitumumab)

Checkmark P1 data (Solid tumor)
May 2012 - May 2012: P1 data (Solid tumor)
Completed
1
56
US
bevacizumab, everolimus, panitumumab, avastin, RAD001
Herbert Hurwitz, MD, Novartis, Genentech, Inc., Amgen
Solid Tumors
09/14
09/14
NCT00804336: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Completed
1
22
US
SOM230, pasireotide, RAD001
Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital, Novartis
Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
09/14
04/15
BARIS, NCT01349296: BIBF 1120 and RAD001 in Solid Tumors - Phase I

Checkmark WCLC 2013
Oct 2013 - Oct 2013: WCLC 2013
Completed
1
18
Europe
Everolimus + BIBF 1120, Everolimus, RAD001, Afinitor, BIBF 1120
University of Cologne, Boehringer Ingelheim
Solid Tumors
10/14
05/16
NCT01700400: Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer

Completed
1
13
US
Everolimus, Afinitor, Zortress, RAD001, Pemetrexed, Alimta, Carboplatin, Paraplatin, CBDCA, Bevacizumab, Avastin
Cancer Research and Biostatistics Clinical Trials Consortium, University of Arizona, Providence Cancer Center, Earle A. Chiles Research Institute, Novartis Pharmaceuticals
Non Small Cell Lung Cancer
10/14
10/14
NCT01122199: Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P1 data
May 2011 - May 2011: P1 data
Checkmark P1 data
More
Completed
1
27
US
RAD001 + AMG479, everolimus + ganitumab
Shadia Jalal, Amgen, Novartis
Neoplasm Metastases
01/15
01/15
NCT01482156: Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Completed
1
46
Europe, US, RoW
RAD001 + BEZ235, Afinitor
Novartis Pharmaceuticals
Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
02/15
02/15
NCT01334502: Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

Checkmark ICML 2015
Jun 2015 - Jun 2015: ICML 2015
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
1
26
US
rituximab, cyclophosphamide, doxorubicin hydrochloride, everolimus, prednisone, vincristine sulfate
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Lymphoma
02/15
08/17
NCT01088048: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Checkmark At EHA 2016
Jul 2016 - Jul 2016: At EHA 2016
Checkmark Patterns of treatment-emergent lymphocytosis in CLL/SLL at ASCO 2016
Jun 2016 - Jun 2016: Patterns of treatment-emergent lymphocytosis in CLL/SLL at ASCO 2016
Checkmark ASCO 2015
More
Completed
1
241
US
Idelalisib, GS-1101, CAL-101, Zydelig®, Rituximab, Rituxan, Bendamustine, Treanda, Ofatumumab, Arzerra, Fludarabine, Fludara, Everolimus, Afinitor, RAD-001, Bortezomib, Velcade, codenamed PS-341, Chlorambucil, Leukeran, Lenalidomide, Revlimid
Gilead Sciences
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
04/15
04/15
ChiCTR-IPC-14005473: Comparative Fasting Bioavailability of Two Everolimus Formulations in Healthy Male Chinese Volunteers: An Open-Label, Randomized, Single-Dose, Two-Way Crossover Study

Not yet recruiting
1
24
 
RT(1.5MG) ;TR(1.5mg each period)
the First Affiliated Hospital, College of Medicine, Zhejiang University; Level of the institution:, Shandong Xinshidai Pharmaceutical Co., Ltd.
Healthy Volunteers
 
 
ChiCTR-IPR-14005691: Comparative Fasting Bioavailability of Two Everolimus Formulations in Healthy Male Chinese Volunteers: An Open-Label, Randomized, Single-Dose, Two-Way Crossover Study

Not yet recruiting
1
24
 
RT(1.5MG) ;TR(1.5mg each period)
the First Affiliated Hospital, College of Medicine, Zhejiang University; Level of the institution:, Shandong Xinshidai Pharmaceutical Co., Ltd.
Healthy Volunteers
 
 
NCT00756340: A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors

Completed
1
16
US
Bevacizumab, Avastin(R), Everolimus, RAD001, Afinitor(R)
St. Jude Children's Research Hospital, Novartis Pharmaceuticals
Recurrent or Refractory Solid Tumors, CNS Malignancies
09/15
09/15
NCT00671112: Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Terminated
1
30
US
Bortezomib, Velcade, Everolimus, RAD001
Brian Hill, MD, PhD, National Cancer Institute (NCI), The Leukemia and Lymphoma Society
714leukemia, Lymphoma
10/15
 
NCT02616848: Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Unknown status
1
1
Europe
Everolimus, Eribulin
Istituti Ospitalieri di Cremona
Triple Negative Breast Cancer
11/15
 
NCT01733004: A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Checkmark AACR 2015
Jul 2015 - Jul 2015: AACR 2015
Checkmark ASCO-GI 2015
Jan 2015 - Jan 2015: ASCO-GI 2015
Checkmark Presentation of P1 data for advanced solid tumors (tumor type not specified) at ASCO 2014
More
Completed
1
42
US, Europe
MM-141
Merrimack Pharmaceuticals
Hepatocellular Carcinoma
01/16
 
NCT01182168: Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

Checkmark ASCO-GU 2015
Feb 2015 - Feb 2015: ASCO-GU 2015
Completed
1
12
US
gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals
Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
03/16
03/16
2012-000299-40: A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects

 
1
40
US
Everolimus, RAD001, Tablet
Novartis Pharma Services AG, Novartis Pharma Services AG
Healthy volunteers, Not applicable, Diseases [C] - Cancer [C04]
 
 
NCT01341834: Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

Checkmark ECCO-ESMO-ESTRO 2013
Sep 2013 - Sep 2013: ECCO-ESMO-ESTRO 2013
Checkmark P1 data-ASCO
Jun 2012 - Jun 2012: P1 data-ASCO
Unknown status
1
49
RoW
LBH589 and RAD001
National Cancer Centre, Singapore, Novartis
Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
06/16
12/18
COEB071X2103, NCT01854606 / 2013-001265-16: Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma

Completed
1
31
Europe, US, RoW
AEB071, sotrastuarin, Everolimus, RAD001
Novartis Pharmaceuticals
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
06/16
06/16
NCT02123823 / 2013-001110-15: BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Hourglass Jan 2017 - Dec 2017 : For metastatic breast cancer
Completed
1
164
Europe, RoW
Everolimus, Exemestane, BI 836845, xentuzumab
Boehringer Ingelheim
Neoplasms
11/16
12/21
NCT01523977: Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Completed
1
22
US
Everolimus, RAD-001, Prednisone, Vincristine, PEG-Asparaginase, Oncaspar, Doxorubicin, Dexrazoxane, Zinecard
Dana-Farber Cancer Institute, Novartis
Acute Lymphoblastic Leukemia
01/17
11/18
NCT01548807: Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

Completed
1
19
US
Everolimus (RAD001)
Abramson Cancer Center of the University of Pennsylvania
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
01/17
01/17
NCT01184326: Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Completed
1
23
US
pazopanib, Votrient, everolimus, RAD001
Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, GlaxoSmithKline, Novartis
Solid Tumor, Kidney Cancer
03/17
03/17
NCT02063958: Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

Completed
1
19
US
SNX-5422
Esanex Inc.
Cancer
03/17
03/18
NCT01470209: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Completed
1
43
US
BKM120, Buparlisib, Everolimus, RAD001, Afinitor
Emory University, Novartis Pharmaceuticals
Solid Tumors, Lung Cancer
05/17
05/17
NCT02454478: Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Completed
1
7
Japan
Lenvatinib, Everolimus, Lenvatinib plus Everolimus orally once a day
Eisai Co., Ltd.
Carcinoma, Renal Cell
05/17
05/17
 

Download Options